STOCK TITAN
  1. Home
  2. News
  3. IMMP

Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.

Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.

At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.

In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.

Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.

For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.

News

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary
Immutep receives positive feedback from the Spanish Medicines Agency for the upcoming TACTI-004 registrational trial in metastatic non-small cell lung cancer. The AEMPS supports Immutep moving into a registrational trial in 1L NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Rhea-AI Summary
Immutep Limited announces positive safety and initial efficacy data from the AIPAC-003 trial, showing encouraging results in metastatic breast cancer patients. The combination of 90mg efti with paclitaxel is safe and well-tolerated, with a 50% overall response rate and a 100% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.06%
Tags
clinical trial
-
News

Immutep Quarterly Activities Report Q2 FY24

Rhea-AI Summary
Immutep Limited (IMMP) reports promising clinical data from various phase II and III trials, including strong overall survival and response rates in non-small cell lung cancer patients. The company is well-financed with a cash balance of A$103.7 million, providing cash runway to early CY 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Rhea-AI Summary
Immutep Limited (IMM) Announces Enrollment of First Patient in INSIGHT-005 Phase I Trial for Urothelial Carcinoma Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
none
-
News

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces constructive feedback from the Paul-Ehrlich-Institut regarding the planned TACTI-004 Phase III trial of eftilagimod alpha for first line treatment of metastatic non-small cell lung cancer. The PEI is supportive of Immutep moving into a registrational trial in first line NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy. Immutep plans to announce its final trial design for TACTI-004 in Q1 of CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
News

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The company also received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program. The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
News

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Rhea-AI Summary
Immutep Limited (IMM) announces the expansion of the INSIGHT-003 trial to four sites in Germany, supporting faster enrolment in the study evaluating eftilagimod alpha in combination with KEYTRUDA and doublet chemotherapy for NSCLC. The trial is expected to complete recruitment in 1H CY2024, with promising early clinical data showing a 70.6% overall response rate and 10.9-month median progression-free survival in patients with PD-L1 TPS of <50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
clinical trial
-
News

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the completion of patient enrollment in the TACTI-003 Phase IIb trial evaluating efti in combination with pembrolizumab for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The trial enrolled 171 patients in the US, Europe, and Australia, with the primary endpoint being Overall Response Rate. Results are expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
clinical trial
-
News

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Rhea-AI Summary
Immutep Limited announces the completion of the open-label safety lead-in phase of its AIPAC-003 Phase II/III trial. The trial evaluated the combination of 90mg eftilagimod alpha (efti) with paclitaxel in six patients with metastatic breast cancer. There were no safety or tolerability issues, and the independent Data Monitoring Committee recommended proceeding to the randomized Phase II portion of the trial. The Phase II portion will include up to 58 evaluable patients to determine the optimal biological dose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Rhea-AI Summary
Immutep Limited announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial, showing statistically significant increases in Th1 biomarkers and immune activating genes. The data supports the success of eftilagimod alpha (efti) in first-line treatment of non-small cell lung cancer (NSCLC) patients. The increase in absolute lymphocyte count (ALC) is correlated with positive overall survival results. Similar immune response biomarkers were seen in the AIPAC Phase IIb trial in metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
clinical trial

FAQ

What is the current stock price of Immutep American Depositary Shares (IMMP)?

The current stock price of Immutep American Depositary Shares (IMMP) is $2.03 as of December 20, 2024.

What is the market cap of Immutep American Depositary Shares (IMMP)?

The market cap of Immutep American Depositary Shares (IMMP) is approximately 311.3M.

What is Immutep Limited?

Immutep Limited is a biotechnology company developing innovative immunotherapy products for cancer and autoimmune diseases.

What products does Immutep specialize in?

Immutep specializes in products based on the LAG-3 immune control mechanism, including IMP321 for cancer chemo-immunotherapy, and other LAG-3 related products like IMP701 and CVac.

What is the LAG-3 immune control mechanism?

The LAG-3 immune control mechanism is crucial for regulating the T cell immune response and is used by Immutep in developing therapies for cancer and autoimmune diseases.

What is IMP321?

IMP321 is a T cell immunostimulatory factor (APC activator) developed by Immutep for cancer chemo-immunotherapy. It has completed Phase II clinical trials.

What are the other key products in Immutep's pipeline?

Other key products include IMP701, a blocking anti-LAG-3 antibody for cancer, and CVac, a personalized immunocellular therapeutic for epithelial cancer.

With which markets is Immutep affiliated?

Immutep is listed on the Australian Stock Exchange and the Nasdaq Global Market in the U.S.

Where is Immutep headquartered?

Immutep is headquartered in Australia.

What are Immutep's key partnerships?

Immutep collaborates with large pharmaceutical companies to develop and bring its products to market.

How does Immutep generate revenue?

Immutep generates the majority of its revenue from the sale of its biotechnology products.

Why should investors consider Immutep?

Investors should consider Immutep for its cutting-edge research, promising clinical advancements in immunotherapy, and strategic partnerships.

Stock IMMP logo
Immutep Limited American Depositary Shares

Nasdaq:IMMP

IMMP Rankings

#3494 Ranked by Market Cap
N/A Ranked by Dividends

IMMP Stock Data

311.28M
145.44M
0.01%
6.26%
3.53%
Biotechnology
Healthcare
Link
United States of America
Sydney